Cardiovascular Diseases
Disease State Hub
Featured
09/15/2026
Anthony Calabro, MA
In a post hoc analysis of the randomized CLEAR Outcomes trial, bempedoic acid 180 mg reduced first major adverse limb events (MALE) by 36% and total MALE by 45% versus placebo among statin-intolerant...
09/15/2026
09/15/2026
Anthony Calabro, MA
In a prespecified secondary analysis of the phase 3 SELECT trial, once-weekly semaglutide 2.4 mg reduced high-sensitivity C-reactive protein by 37.8% versus placebo at 104 weeks among adults with...
09/15/2026
09/09/2026
Anthony Calabro, MA
Recent US claims data offer insight into how transthyretin amyloid cardiomyopathy’s diagnosed incidence, prevalence, and associated clinical burden have changed over time.
09/09/2026
Interactive Features
09/09/2026
Anthony Calabro, MA
Recent US claims data offer insight into how transthyretin amyloid cardiomyopathy’s diagnosed incidence, prevalence, and associated clinical burden have changed over time.
09/09/2026
08/25/2026
Anthony Calabro, MA
Five-year survival after Hodgkin lymphoma does not eliminate excess mortality risk. What does the long-term pattern of deaths reveal about survivorship after the disease?
08/25/2026
08/08/2026
Anthony Calabro, MA
A 29-year-old woman with systemic lupus erythematosus and a history of hypertension presented to the emergency department with acute chest pain and lower extremity paresthesia.
08/08/2026
03/26/2026
Kate Young
Diabetes mellitus represents one of the most powerful and prevalent cardiometabolic risk factors facing U.S. adults today. Test your knowledge about diabetes prevalence.
03/26/2026
03/23/2026
Ashton L. Stahl
Test your knowledge on the prevalence of FDA-approved indications for novel cardiovascular-kidney-metabolic therapies and the implications for clinical practice.
03/23/2026
Clinical Insights
03/06/2026
Anum Saeed, MD
In this Q&A, Anum Saeed, MD discusses how cardiologists must think beyond LDL and blood pressure, leveraging GLP-1 receptor agonists, SGLT-2 inhibitors, and emerging therapies to reduce cardiovascular...
03/06/2026
NUTRITION411: THE PODCAST, EP. 54
NUTRITION411: THE PODCAST, EP. 54
02/11/2026
Lisa Jones, MA, RDN, LDN, FAND; Grace A. Derocha, MBA, RD, CDCES
In part two of this four-part series, Lisa Jones, MA, RDN, LDN, FAND, and Grace A. Derocha, MBA, RD, CDCES, registered dietitian and a certified diabetes care and education specialist, discuss how...
02/11/2026
02/05/2026
Brian A. Bergmark, MD
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
02/05/2026
Nutrition411: The Podcast, Ep. 53
Nutrition411: The Podcast, Ep. 53
02/04/2026
Lisa Jones, MA, RDN, LDN, FAND; Grace A. Derocha, MBA, RD, CDCES
In part one of this four-part series, Lisa Jones, MA, RDN, LDN, FAND, and Grace A. Derocha, MBA, RD, CDCES, registered dietitian and a certified diabetes care and education specialist, discuss the latest...
02/04/2026
04/15/2025
Rachel Lampert, MD
In this video, Rachel Lampert, MD, Robert W. Berliner Professor of Internal Medicine at the Yale School of Medicine, reviews her presentation at the American College of Cardiology 2025 Annual Meeting,...
04/15/2025
